{"id":836412,"date":"2025-04-10T16:35:29","date_gmt":"2025-04-10T20:35:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/"},"modified":"2025-04-10T16:35:29","modified_gmt":"2025-04-10T20:35:29","slug":"bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/","title":{"rendered":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant"},"content":{"rendered":"
\n

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) — Today, eXoZymes Inc. (NASDAQ: EXOZ) (\u201ceXoZymes\u201d) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals – announced its latest initiative – BioClick<\/i> – a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant<\/a> from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created.<\/p>\n

At the heart of BioClick<\/i> is a focus on group transfer reactions<\/i>, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the 2022 Nobel Prize in Chemistry<\/a> concept of Click Chemistry, <\/i>often described as snapping LEGO pieces together, BioClick is now enabling new types of group transfers using custom enzymes. Among these, prenylation<\/i> is a standout: a process where a small fatty molecular group is taken from a donor molecule and added to another drug compound to improve its function or how well it works in the body. This technique is especially promising in the development of more effective, targeted drugs and therapies, either as new drugs or as better versions of existing drugs.<\/p>\n

\u201cOur new BioClick approach not only boosts efficiency but opens the door to the biomanufacturing of rare and previously unthinkable target molecules that can be game-changers in medicine, nutrition, and other functional nutraceuticals. By building a complete tool set\u2014from enzyme engineering to pilot scale synthesis, we\u2019re setting a new standard for what can be done with bio-based click chemistry.<\/i>\u201d Said Dr. John Billingsley, PI on the recently awarded BioClick grant from NIH\u2019s Small Business Innovation Research (SBIR) program. He adds, \u201cIf you consider directed evolution, which landed Dr. Francis H. Arnold the Nobel Prize in chemistry in 2018 as the first generation, and rational protein design as the second generation, we\u2019re now introducing the third generation of enzyme engineering: Artificial Evolution.\u201d<\/i><\/p>\n

Critically, the BioClick tools also introduce new high-throughput screening<\/i> capabilities, allowing researchers to test thousands of enzyme variations simultaneously. With the help of advanced tools like mass spectrometry and cutting-edge data analysis algorithms, eXoZymes can quickly identify which enzyme version works best for a given group transfer reaction – greatly enhancing the molecular level operation by quickly identifying the best-performing variants. This Artificial Evolution<\/i> process dramatically reduces the time and cost required to develop the exozyme pathway that will produce a new or better drug.<\/p>\n

\u201cWith our new BioClick tool set that incorporates artificial intelligence into our exozymes platform, coupled with our advanced enzyme engineering skills and high-throughput screening – which exponentially increases the rate of data acquisition – we now support the automated design of novel small molecules, that will lead to better medicines,<\/i>\u201d states Dr. Tyler Korman, co-founder and VP of Research at eXoZymes. He continues, \u201cIn other words, we\u2019re not just fine-tuning our pathways of enzymes and exozymes for drug development – we\u2019re unlocking a large new white space of small molecules previously inaccessible. We believe this has the potential to introduce not just new drugs but a valuable opportunity of taking existing drugs and making better versions of them.\u201d<\/i><\/p>\n

\n Acknowledgement
<\/b>Research reported in this press release was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R43GM157956. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.<\/p>\n

\n About eXoZymes
<\/b>Founded in 2019, the company has developed a biomanufacturing platform that – as a historic first – offers the tools and insights to engineer, control and optimize nature\u2019s own natural processes to produce chemical compounds, enabling the company\u2019s partners to replace traditional chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.<\/p>\n

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.<\/p>\n

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.<\/p>\n

While the company, eXoZymes Inc., has introduced \u201cexozymes\u201d as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.<\/p>\n

Learn more on exozymes.com<\/a>. <\/p>\n

\n eXoZymes Safe Harbor<\/b>\n <\/p>\n

This press release<\/i> includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company\u2019s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as \u201cbelieve,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cseek,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely\u201d or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release<\/i> regarding the company\u2019s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the \u201cRisk Factors\u201d section of eXoZymes\u2019 quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.\u00a0<\/p>\n

\n eXoZymes contact<\/b>
\n
Lasse G\u00f6rlitz, VP of Communications
(858) 319-7135
press@exozymes.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) — Today, eXoZymes Inc. (NASDAQ: EXOZ) (\u201ceXoZymes\u201d) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals – announced its latest initiative – BioClick – a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the … <\/p>\n

Continue reading “BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-836412","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) — Today, eXoZymes Inc. (NASDAQ: EXOZ) (\u201ceXoZymes\u201d) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals – announced its latest initiative – BioClick – a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the … Continue reading "BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T20:35:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant\",\"datePublished\":\"2025-04-10T20:35:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/\"},\"wordCount\":1053,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/\",\"name\":\"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==\",\"datePublished\":\"2025-04-10T20:35:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/","og_locale":"en_US","og_type":"article","og_title":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk","og_description":"Monrovia, CA, April 10, 2025 (GLOBE NEWSWIRE) — Today, eXoZymes Inc. (NASDAQ: EXOZ) (\u201ceXoZymes\u201d) – a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals – announced its latest initiative – BioClick – a pioneering concept designed to enhance and accelerate the engineering of enzymes for advanced chemical reactions. Funded in part by a $300K grant from the National Institutes of Health (NIH), this project has the potential to revolutionize how medicines and other bio-based compounds are created. At the heart of BioClick is a focus on group transfer reactions, a class of biochemical reactions that allow enzymes to precisely move small molecular chemical groups from one compound to another. Inspired by the … Continue reading \"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-10T20:35:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant","datePublished":"2025-04-10T20:35:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/"},"wordCount":1053,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/","name":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==","datePublished":"2025-04-10T20:35:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMDY1NSM2ODYxNzAyIzUwMDExOTMyNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioclick-an-enzyme-engineering-game-changer-launched-by-exozymes-and-supported-by-a-300k-nih-grant\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioClick \u2013 an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=836412"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/836412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=836412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=836412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=836412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}